N/A N=6 Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers
Pharmacodynamic
Primary: Change in Gastric pH After Administration of Betaine Hydrochloride (HCl) — 4.54 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=11 Gastric pH and Anthocyanin Absorption
Anthocyanin Metabolism
Primary: Gastric pH — 0.96; 2.31 pH
Phase 1 N=105 Duration of Effect of Acidform Gel on Vaginal pH
Healthy
Primary: Change in Vaginal pH Following a Single Dose of Acidform (3, 4, and 5 g), HEC Placebo (4 g), or no Intervention. — 4.85; 4.81; 4.91; 5.00 pH
Phase 3 N=63 Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)
Human Experimentation
Primary: Achievement of Sustained Difference in Inhibition of Intragastric Acidity Based on Median pH Values Between the Two Active Study Treatments at Steady-state on Day 7…
Phase 4 N=39 Gastric Acid Suppression and Probiotic Colonization
Probiotics
Primary: Relative Abundance of VSL#3 Probiotic Bacterial Strains When Ingested in the Presence or Absence of the Proton Pump Inhibitor (PPI) Omeprazole at Week 4. — 1.002; 0.8186…
Phase 4 N=12 The Effect of Protein on Calcium Absorption and Gastric Acid Production
Osteoporosis
Primary: Percent Change in Intestinal Calcium Absorption — 34.2; 31.5 percentage of calcium absorption
Phase 2 N=73 Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
N/A N=449 Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
Esophagogastroduodenoscopy · Colonoscopy
Primary: Residual Gastric Volumes of Different Bowel Preparation Regimens — 19; 16; 18 mL
Phase 4 N=40 Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression
Healthy
Primary: Mean Percent Time That Gastric pH > 4.0 on Day 5 — 36.8; 45.7 percent time gastric pH exceeds 4.0 — p=< 0.0001
Phase 4 N=30 Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
Normal Healthy Subject Population
Primary: The Mean Percent Time Gastric pH > 4.0 on Day 1
N/A N=126 Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia
Stomach Neoplasms · Metaplasia
Primary: Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy — 78.5; 94.4; 89.2; 67.1 percentage of lesions
Phase 4 N=60 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
Diabetes Mellitus, Type 2 · Obesity · Gastroparesis
Primary: Presence of RGV (Residual Gastric Volume) in Stomach — 7; 1 Participants
N/A N=146 Aspiration of Residual Gastric Contents
Infant, Premature · Nutrition, Enteral
Primary: Enteral Intake on Day of Life 7 — 27.5; 22.6 mL/kg per day — p=0.27
Phase 4 N=12 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis
Gastroparesis · Gastroesophageal Reflux Disease
Primary: Time to Maximal Omeprazole Concentration (Tmax) — 32; 97 minutes — p=< 0.01
N/A N=76 Proteiomic Fingerprints of Gastric Juice
Gastric Cancer
Primary: Number of Participants With Accurate Diagnosis for Gastric Cancer — 27; 44 participants
N/A N=100 Gastric Ultrasound
Surgery
Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants
Phase 1 N=12 Effect of Calcium Glycerophosphate (CaGP) - Fluoride Dentifrice on Dental Biofilm pH
Dental Caries
Primary: Minimum pH — 5.40; 5.48; 5.25; 5.70 pH — p=0.001
Phase 3 N=30 Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)
Intragastric Acidity
Primary: Percent Time With Intragastric pH>4 During the First 4 Hours Following Administration on Day 4 of Treatment — 53.265; 46.933; 17.215 Percentage of Time
Phase 3 N=45 Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients
Gastroesophageal Reflux Disease
Primary: Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 4 — 5.14; 14.94 percentage of time with pH below pH 4 — p=0.0003
Phase 3 N=6 Effect on Bacterial Glycolytic Acid Formation on Plaque
Dental Plaque
Primary: ph of Dental Plaque After Sucrose Challenge — 4.88; 5.04; 4.98 ph of dental plaque — p=0.05
Phase 4 N=72 Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide
Pregnancy · Cesarean Section · Aspiration
Primary: Change in Gastric Volume (mL) — -1; -2; 0; 1 Milliliters — p=.001
N/A N=39 Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
Gastroesophageal Reflux Disease
Primary: Patients Requiring Endoscopic Removal of BRAVO Because of Reported Discomfort — 2; 0 participants
N/A N=63 Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy
GERD
Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes
Phase 3 N=26 A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
Non-erosive Gastroesophageal Reflux Disease
Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…
Phase 4 N=52 Role of Pepsin Assay in Wheezy Infants
Gastroesophageal Reflux Disease
Primary: Number of Participants in Each Level of Wheeze Control — 18; 11; 9 Participants
Phase 4 N=14 Effects of Gastric Acid on Colonic Microbiome
Clostridium Difficile
Primary: Shannon Diversity Index Measuring Change in Microbiome Diversity — 0.18; 0.14 Shannon index — p=0.71
N/A N=9 Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.
Gastroparesis
Primary: Gastric Accommodation — 322.22; 402.78; 450.63 ml
Phase 2 N=120 Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn
Heartburn
Primary: Measure: Number of Participants With no Heartburn (Post Treatment) Following Consumption of Heartburn-inducing Meal — 0; 2; 1; 0 participants
N/A N=10 Transmitted Light Tissue Thickness Analysis (TiLTT)
Morbid Obesity
Primary: Number of Patients With Transmitted Light Intensity to Gastric Wall Thickness) — 10 Participants
Phase 3 N=75 Efficacy of Lansoprazole in Chronic Post Nasal Drip
Larynx Disease
Primary: Post Nasal Drainage Symptom Response — 55; 3.5; 50; 5 Scores on a Scale — p=.01